Journey Medical (DERM) to Release Quarterly Earnings on Monday

Key Points

• Journey Medical is set to release its Q2 2025 earnings on August 11th, with analysts expecting a loss of ($0.06) per share and revenue of $14.93 million.
• The company previously reported a loss of ($0.18) per share for Q1 2025, surpassing expectations and achieving revenue of $13.14 million.
• Journey Medical's stock has a market cap of $163.79 million and recently opened at $7.03, with analysts issuing mixed ratings on its shares.

Journey Medical (NASDAQ:DERM - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Journey Medical to post earnings of ($0.06) per share and revenue of $14.93 million for the quarter.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.06. The company had revenue of $13.14 million during the quarter, compared to analyst estimates of $12.05 million. Journey Medical had a negative net margin of 14.76% and a negative return on equity of 52.03%. On average, analysts expect Journey Medical to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Journey Medical Trading Up 0.6%

NASDAQ DERM opened at $7.03 on Monday. The firm has a market cap of $163.79 million, a PE ratio of -18.03 and a beta of 0.80. Journey Medical has a 52 week low of $3.54 and a 52 week high of $8.25. The company has a quick ratio of 1.03, a current ratio of 1.34 and a debt-to-equity ratio of 1.07. The company has a 50 day moving average price of $7.19 and a 200 day moving average price of $6.29.

Analysts Set New Price Targets

A number of analysts recently issued reports on DERM shares. Alliance Global Partners reissued a "buy" rating on shares of Journey Medical in a report on Thursday, May 15th. Wall Street Zen cut shares of Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th.

Institutional Trading of Journey Medical

An institutional investor recently bought a new position in Journey Medical stock. Jane Street Group LLC bought a new stake in Journey Medical Corporation (NASDAQ:DERM - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 18,599 shares of the company's stock, valued at approximately $110,000. Jane Street Group LLC owned 0.08% of Journey Medical at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.25% of the company's stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.